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Recommendations {#anae14904-sec-0001}
===============

Awake tracheal intubation must be considered in the presence of predictors of difficult airway management.A cognitive aid such as a checklist is recommended before and during performance of awake tracheal intubation.Supplemental oxygen should always be administered during awake tracheal intubation.Effective topicalisation must be established and tested. The maximum dose of lidocaine should not exceed 9 mg.kg^−1^ lean body weight.Cautious use of minimal sedation can be beneficial. This should ideally be administered by an independent practitioner. Sedation should not be used as a substitute for inadequate airway topicalisation.The number of attempts should be limited to three, with one further attempt by a more experienced operator (3 + 1).Anaesthesia should only be induced after a two‐point check (visual confirmation and capnography) has confirmed correct tracheal tube position.All departments should support anaesthetists to attain competency and maintain skills in awake tracheal intubation.

Why were these guidelines developed? {#anae14904-sec-0002}
====================================

Awake tracheal intubation (ATI) has a high success rate and a low‐risk profile and has been cited as the gold standard in airway management for a predicted difficult airway. However, ATI is reported to be used in as few as 0.2% of all tracheal intubations in the UK [1](#anae14904-bib-0001){ref-type="ref"}. There are barriers preventing broad uptake and use of awake techniques for securing the airway. We aimed to produce generalisable guidelines to improve patient safety by making ATI more accessible to all clinicians, trainers and institutions. Rather than inform expert practice, these guidelines aim to support the use of ATI by more clinicians, with a particular focus on those that do not regularly perform ATI. There remains heterogeneity in clinical practice, underscoring the need for a more consistent approach using the available evidence, which these guidelines aim to deliver.

What other guidelines exist? {#anae14904-sec-0003}
============================

Although there are many guidelines on unanticipated difficult airway management [2](#anae14904-bib-0002){ref-type="ref"}, [3](#anae14904-bib-0003){ref-type="ref"}, [4](#anae14904-bib-0004){ref-type="ref"}, [5](#anae14904-bib-0005){ref-type="ref"}, [6](#anae14904-bib-0006){ref-type="ref"}, [7](#anae14904-bib-0007){ref-type="ref"}, [8](#anae14904-bib-0008){ref-type="ref"}, [9](#anae14904-bib-0009){ref-type="ref"}, [10](#anae14904-bib-0010){ref-type="ref"}, [11](#anae14904-bib-0011){ref-type="ref"}, [12](#anae14904-bib-0012){ref-type="ref"}, [13](#anae14904-bib-0013){ref-type="ref"}, there are few that specifically focus on the anticipated difficult airway. The ASA, Canadian Airway Focus Group, French Society for Anesthesia and Intensive Care and German Society for Anesthesiology and Intensive Care describe clinical decision making in the anticipated difficult airway [6](#anae14904-bib-0006){ref-type="ref"}, [7](#anae14904-bib-0007){ref-type="ref"}, [10](#anae14904-bib-0010){ref-type="ref"}, [12](#anae14904-bib-0012){ref-type="ref"}.

How do these guidelines differ from existing guidelines? {#anae14904-sec-0004}
========================================================

At the time of writing, there were no nationally or internationally agreed guidelines on the practical performance of ATI.

Disclaimer {#anae14904-sec-0005}
==========

These guidelines are not intended to represent a minimum standard of practice, nor are they to be regarded as a substitute for good clinical judgement. They present key principles and suggested strategies for preparation, performance, consent and training to inform clinical practice. This document is intended to guide appropriately trained operators.

Introduction {#anae14904-sec-0006}
============

A strategy for difficult airway management is necessary when facemask ventilation, supraglottic airway device (SAD) placement or ventilation, tracheal intubation or insertion of a front‐of‐neck airway (FONA) is predicted to be challenging. The incidence of difficult facemask ventilation is 0.66--2.5% [14](#anae14904-bib-0014){ref-type="ref"}, [15](#anae14904-bib-0015){ref-type="ref"}, [16](#anae14904-bib-0016){ref-type="ref"}, [17](#anae14904-bib-0017){ref-type="ref"}, difficult SAD placement or ventilation 0.5--4.7% [18](#anae14904-bib-0018){ref-type="ref"}, [19](#anae14904-bib-0019){ref-type="ref"}, [20](#anae14904-bib-0020){ref-type="ref"}, [21](#anae14904-bib-0021){ref-type="ref"}, [22](#anae14904-bib-0022){ref-type="ref"}, difficult tracheal intubation 1.9--10% [14](#anae14904-bib-0014){ref-type="ref"}, [16](#anae14904-bib-0016){ref-type="ref"}, [23](#anae14904-bib-0023){ref-type="ref"}, [24](#anae14904-bib-0024){ref-type="ref"}, [25](#anae14904-bib-0025){ref-type="ref"} and combined difficulty in both facemask and tracheal intubation 0.3--0.4% [16](#anae14904-bib-0016){ref-type="ref"}. As a rescue technique after failed tracheal intubation, one study reported that SADs have a success rate as low as 65% in difficult airway management [26](#anae14904-bib-0026){ref-type="ref"}. The reported incidence of requirement for emergency FONA and death due to airway management are 0.002--0.07% (1:50,000--1:1400) [1](#anae14904-bib-0001){ref-type="ref"}, [27](#anae14904-bib-0027){ref-type="ref"}, [28](#anae14904-bib-0028){ref-type="ref"} and 0.0006--0.04% (1:180,000--1:2800), respectively [1](#anae14904-bib-0001){ref-type="ref"}, [28](#anae14904-bib-0028){ref-type="ref"}. The risk and severity of adverse outcomes during difficult airway management is highlighted by the plethora of guidelines and cognitive aids for airway rescue [29](#anae14904-bib-0029){ref-type="ref"}.

Awake tracheal intubation involves placing a tracheal tube in an awake, spontaneously‐breathing patient, most commonly with flexible bronchoscopy (ATI:FB) or videolaryngoscopy (ATI:VL, Table [1](#anae14904-tbl-0001){ref-type="table"}). This allows the airway to be secured before induction of general anaesthesia, avoiding the potential risks and consequences of difficult airway management in an anaesthetised patient [30](#anae14904-bib-0030){ref-type="ref"}.

###### 

A summary of terms used in these guidelines

+-----------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Term                  | Definition                                                                                                                                                             |
+=======================+========================================================================================================================================================================+
| ATI                   | Awake tracheal intubation                                                                                                                                              |
+-----------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| ATI:FB                | Awake tracheal intubation using flexible bronchoscopy                                                                                                                  |
+-----------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| ATI:VL                | Awake tracheal intubation using videolaryngoscopy                                                                                                                      |
+-----------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| FONA                  | Front‐of‐neck airway                                                                                                                                                   |
+-----------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| sTOP                  | Sedation, topicalisation, oxygenation, performance                                                                                                                     |
+-----------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Minimal sedation      | Drug‐induced state during which the patient responds normally to verbal commands, while the airway, spontaneous ventilation and cardiovascular function are unaffected |
+-----------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Airway topicalisation | Topical application of local anaesthetic to the airway                                                                                                                 |
+-----------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Performance           | The practical conduct of awake tracheal intubation                                                                                                                     |
+-----------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Two‐point check       | 1\. Visualisation of the tracheal lumen with ATI:FB or tracheal tube through the cords with ATI:VL to confirm tracheal placement                                       |
|                       |                                                                                                                                                                        |
|                       | 2\. Capnography to exclude oesophageal intubation                                                                                                                      |
+-----------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Unsuccessful attempt  | Unplanned removal of flexible bronchoscope, videolaryngoscope or tracheal tube from the airway                                                                         |
+-----------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Unsuccessful ATI      | Successful tracheal intubation not achieved after 3 + 1 attempts[a](#anae14904-note-0001){ref-type="fn"}                                                               |
+-----------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------+

Three attempts by the primary operator and a fourth attempt by a more experienced operator.

John Wiley & Sons, Ltd

Awake tracheal intubation has a favourable safety profile because both spontaneous ventilation and intrinsic airway tone are maintained until the trachea is intubated [31](#anae14904-bib-0031){ref-type="ref"}, [32](#anae14904-bib-0032){ref-type="ref"}, [33](#anae14904-bib-0033){ref-type="ref"}, [34](#anae14904-bib-0034){ref-type="ref"}, [35](#anae14904-bib-0035){ref-type="ref"}. Awake tracheal intubation can be unsuccessful in 1--2% of cases, but this rarely leads to airway rescue strategies or death [33](#anae14904-bib-0033){ref-type="ref"}, [34](#anae14904-bib-0034){ref-type="ref"}, [35](#anae14904-bib-0035){ref-type="ref"}. These guidelines aim to increase the use of ATI by providing clear guidance for clinicians to support decision making, preparation and performance of ATI in the setting of a predicted difficult airway.

Methods {#anae14904-sec-0007}
=======

The development of these guidelines followed the appraisal of guidelines for research and evaluation (AGREE) reporting checklist [36](#anae14904-bib-0036){ref-type="ref"}. To ensure these guidelines are supported by best evidence, a systematic review adhering to the preferred reporting items for systematic reviews and meta‐analyses (PRISMA) recommendations [37](#anae14904-bib-0037){ref-type="ref"} was performed. We sought published data of relevance to ATI, including decision making, technical performance, complications, training and non‐technical aspects. Details of the search, screening and study selection are shown in the supplementary material (Supporting Information, Appendix [S1](#anae14904-sup-0001){ref-type="supplementary-material"}).

Data from included studies were synthesised and consensus from all 10 members of the guideline group was sought to formulate guideline recommendations using a three‐round Delphi method [38](#anae14904-bib-0038){ref-type="ref"}, [39](#anae14904-bib-0039){ref-type="ref"}. The first round entailed an initially proposed longlist of recommendations, which were each reviewed and rated for content and clarity. The recommendations in which six or more members of the guideline group approved were shortlisted. A second round of rating was then undertaken, in which the highest rated recommendations were selected. Finally, a third round involving recommendation‐ratification in round‐table discussions was undertaken. These recommendations were based on a number of factors, including: volume and consistency of supportive evidence; applicability and generalisability of the evidence to current practice; and clinical and practical implications of recommendations.

We determined the level of evidence and graded the strength of subsequent recommendations using a modified version of the system developed by the Centre for Evidence‐based Medicine (Oxford, UK) (Table [2](#anae14904-tbl-0002){ref-type="table"}) [40](#anae14904-bib-0040){ref-type="ref"}. Each recommendation was graded A to D according to the strength of the available evidence [41](#anae14904-bib-0041){ref-type="ref"}.

###### 

Grading of recommendations based on the level of evidence available

  Grade   Level of evidence available
  ------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  A       Consistent systematic reviews of RCTs, single RCTs or all‐or‐none studies
  B       Consistent systematic reviews of low‐quality RCTs or cohort studies, individual cohort study, or epidemiological outcome studiesConsistent systematic reviews of case--control studies, individual case--control studiesExtrapolations from systematic reviews of RCTs, single RCTs or all‐or‐none studies
  C       Case series, case reportsExtrapolations from systematic reviews of low‐quality RCTs, cohort studies or case--control studies, individual cohort study, epidemiological outcome studies, individual case--control studiesExtrapolations from systematic reviews of case--control studies
  D       Expert opinion or ideas based on theory, bench studies or first principles aloneTroublingly inconsistent or inconclusive studies of any level

RCT, randomised controlled trial.

John Wiley & Sons, Ltd

Over 3 years the guideline group met 21 times in person and 14 times remotely in order to develop, draft and finalise these guidelines. Draft versions were presented at the 2017 and 2018 Difficult Airway Society (DAS) annual scientific meetings. We sent an electronic survey to DAS members (n = 2150) to capture their opinions, preferences and clinical experiences in ATI, of whom 632 (29%) responded. This survey highlighted the need for guidelines for ATI and the role of a standardised technique for training and clinical practice. We also performed a survey of 43 international experts, seeking details on commonly used strategies for oxygenation, topicalisation, sedation and performance of ATI. Patient and public involvement was also used to explore the views and experiences of patients who had undergone ATI. This was achieved by conducting a fully anonymised multicentre structured survey of 100 patients, where we explored the self‐reported experiences of the overall conduct of ATI. We consulted an anaesthetic assistant during the preparation of these guidelines and invited a senior anaesthetic nurse and two consultant head and neck surgeons to comment on the final draft. A draft manuscript of these guidelines was then sent to 13 international experts with clinical or academic experience related to ATI to gather specific comments and feedback on recommendations and to assess applicability and feasibility. The guideline group considered the responses from expert reviewers to inform the final recommendations. The final draft of the guideline was then submitted to DAS executive committee for ratification.

Indications {#anae14904-sec-0008}
===========

Prediction of difficult airway management is unreliable [14](#anae14904-bib-0014){ref-type="ref"}, [23](#anae14904-bib-0023){ref-type="ref"}, [42](#anae14904-bib-0042){ref-type="ref"}, but there are common features that have been identified in patients requiring ATI. These include, but are not limited to: patients with head and neck pathology (including malignancy, previous surgery or radiotherapy); reduced mouth opening; limited neck extension; obstructive sleep apnoea; morbid obesity; and progressive airway compromise [32](#anae14904-bib-0032){ref-type="ref"}, [33](#anae14904-bib-0033){ref-type="ref"}, [35](#anae14904-bib-0035){ref-type="ref"}, [43](#anae14904-bib-0043){ref-type="ref"}, [44](#anae14904-bib-0044){ref-type="ref"}. There is limited evidence for any individual, validated, predictive assessment tool developed specifically for ATI. Airway assessment including history, examination and appropriate investigations, is indicated for all patients [1](#anae14904-bib-0001){ref-type="ref"}, [2](#anae14904-bib-0002){ref-type="ref"}, [7](#anae14904-bib-0007){ref-type="ref"}, [45](#anae14904-bib-0045){ref-type="ref"} (Grade D). Awake tracheal intubation must be considered in the presence of predictors of difficult airway management (Grade D). In an elective setting the patient should be appropriately fasted (Grade D). In the non‐fasted patient, the potential for regurgitation or aspiration of gastric contents still exists even with ATI. There are few relative contra‐indications to ATI (e.g. local anaesthetic allergy, airway bleeding, unco‐operative patients) but the only absolute contra‐indication is patient refusal.

Procedural setup {#anae14904-sec-0009}
================

Awake tracheal intubation can be associated with the greatest operator‐related physical, mental and psychological stress of all elective airway management interventions [46](#anae14904-bib-0046){ref-type="ref"}. These stressors may be associated with suboptimal performance [47](#anae14904-bib-0047){ref-type="ref"}, [48](#anae14904-bib-0048){ref-type="ref"}, increasing the risk of complications including failure. Teamwork, good communication and appropriate preparation may mitigate these challenges [48](#anae14904-bib-0048){ref-type="ref"}, [49](#anae14904-bib-0049){ref-type="ref"}, [50](#anae14904-bib-0050){ref-type="ref"} and the importance of well‐trained, competent assistants should not be underestimated. Safety should not be compromised by time pressures presented by other staff members; therefore planning and communication with anaesthetic assistants, operating theatre nursing staff, surgeons and skilled anaesthetic colleagues is essential (Grade D).

Consideration and planning of the appropriate location is essential. Awake tracheal intubation should ideally be performed in the operating theatre environment (Grade D). This setting has ready access to skilled assistance, drugs, equipment and space. For high‐risk patients, including those with significant airway obstruction, hypoxia, respiratory failure, challenging or failed ATI, the operating theatre may have advantages over an anaesthetic room [1](#anae14904-bib-0001){ref-type="ref"}, [51](#anae14904-bib-0051){ref-type="ref"}, such as greater space and immediate surgical assistance. When ATI is performed outside of the theatre environment (e.g. in the critical care unit or the emergency department), the same standards of care should apply (Grade D) [52](#anae14904-bib-0052){ref-type="ref"}.

Monitoring patients' physiological parameters during anaesthetic care mitigates risks and may alert operators to impending complications [53](#anae14904-bib-0053){ref-type="ref"}, [54](#anae14904-bib-0054){ref-type="ref"}, [55](#anae14904-bib-0055){ref-type="ref"}, [56](#anae14904-bib-0056){ref-type="ref"}, [57](#anae14904-bib-0057){ref-type="ref"}. Frequently occurring avoidable complications in ATI that may be detected by monitoring are airway obstruction and hypoventilation secondary to over‐sedation [33](#anae14904-bib-0033){ref-type="ref"}, [34](#anae14904-bib-0034){ref-type="ref"}, [35](#anae14904-bib-0035){ref-type="ref"}, [58](#anae14904-bib-0058){ref-type="ref"}. Disturbances to cardiac rhythm and blood pressure following administration of pharmacological agents for topicalisation and sedation are possible [35](#anae14904-bib-0035){ref-type="ref"}, [59](#anae14904-bib-0059){ref-type="ref"}, [60](#anae14904-bib-0060){ref-type="ref"}, [61](#anae14904-bib-0061){ref-type="ref"}. In accordance with Association of Anaesthetists' guidelines for patients receiving sedation [62](#anae14904-bib-0062){ref-type="ref"}, it is recommended that ECG, non‐invasive blood pressure, pulse oximetry and continuous end‐tidal carbon dioxide monitoring are used throughout the process of ATI (Grade C). It is acknowledged that end‐tidal carbon dioxide monitoring during ATI may be challenging in current practice.

Workspace ergonomics have an impact on performance and safety [51](#anae14904-bib-0051){ref-type="ref"}, [63](#anae14904-bib-0063){ref-type="ref"}, and should be considered before starting the procedure (Grade D; Fig. [1](#anae14904-fig-0001){ref-type="fig"}; Supporting Information, Appendix [S2](#anae14904-sup-0002){ref-type="supplementary-material"}) [52](#anae14904-bib-0052){ref-type="ref"}. This includes optimising the position of patient, operator and assistants, as well as location of equipment and monitors, which should be in the direct line of sight of the operator. There is no consensus on the ideal operator or patient position [64](#anae14904-bib-0064){ref-type="ref"}, [65](#anae14904-bib-0065){ref-type="ref"}, [66](#anae14904-bib-0066){ref-type="ref"}, [67](#anae14904-bib-0067){ref-type="ref"}, but there are physiological and anatomical advantages to having patients sitting up [68](#anae14904-bib-0068){ref-type="ref"}, [69](#anae14904-bib-0069){ref-type="ref"}, [70](#anae14904-bib-0070){ref-type="ref"}.

![Examples of ergonomics for awake tracheal intubation (ATI). The primary operator should have a direct line of sight of the patient, video monitor and patient monitor, as well as immediate access to infusion pumps, anaesthetic machine, suction and oxygen delivery device. If a second anaesthetist is present, they should be positioned with a direct line of sight of the patient and have immediate access to infusion pumps, as well as be able to access all other equipment. The anaesthetic assistant\'s primary position should be with immediate access to the airway trolley, and in proximity to the operator. (a) Awake tracheal intubation performed with the operator positioned facing the patient who is in a sitting up position. (b) Awake tracheal intubation performed with the operator positioned behind the supine/semi‐recumbent patient. This figure forms part of the Difficult Airway Society guidelines for ATI in adults and should be used in conjunction with the text. ©Difficult Airway Society 2019.](ANAE-75-509-g001){#anae14904-fig-0001}

Complications or unsuccessful ATI, although uncommon, should be prepared for [33](#anae14904-bib-0033){ref-type="ref"}, [34](#anae14904-bib-0034){ref-type="ref"}, [35](#anae14904-bib-0035){ref-type="ref"}, and immediate access to emergency drugs, staff and equipment is essential (Grade C). A plan for unsuccessful ATI, including possible postponement, FONA or high‐risk general anaesthesia, should be discussed explicitly and agreed on by all team members before beginning the procedure (Grade D).

It is important to select an appropriate route for tracheal intubation, visualisation device and tracheal tube. The route for tracheal intubation should take into account patient anatomy, surgical access and tracheal extubation plan (Grade D). For example, in patients with limited mouth opening, the nasal approach may be the only option, while in patients having nasal surgery, the oral approach may be the preferred route. There is no evidence or consensus among experts demonstrating superiority of one route if both are feasible [33](#anae14904-bib-0033){ref-type="ref"}, [34](#anae14904-bib-0034){ref-type="ref"}, [35](#anae14904-bib-0035){ref-type="ref"}, [64](#anae14904-bib-0064){ref-type="ref"}, [71](#anae14904-bib-0071){ref-type="ref"}.

Awake tracheal intubation using videolaryngoscopy has a comparable success rate and safety profile to ATI:FB (98.3% each) [31](#anae14904-bib-0031){ref-type="ref"}. Choosing between techniques is based on patient factors, operator skills and availability of equipment (Grade A). For example, in patients with limited mouth opening, a large tongue or fixed flexion deformity of the neck, ATI:FB may be more appropriate. Conversely, patients with airway bleeding may be more suitable for an ATI:VL technique. If the chosen ATI technique is unsuccessful, practitioners should consider using an alternative (e.g. ATI:FB if ATI:VL is unsuccessful or vice versa; Grade D). A combined approach to ATI using both VL and FB has been described [72](#anae14904-bib-0072){ref-type="ref"}, [73](#anae14904-bib-0073){ref-type="ref"}, [74](#anae14904-bib-0074){ref-type="ref"} and could be considered in complex clinical scenarios (Grade D). In a well‐topicalised patient, insertion of an SAD as a conduit for ATI:FB has also been described [75](#anae14904-bib-0075){ref-type="ref"}, [76](#anae14904-bib-0076){ref-type="ref"}, and may provide the benefit of maintaining airway patency. Single‐use flexible bronchoscopes are associated with a similar safety profile to re‐usable ones [77](#anae14904-bib-0077){ref-type="ref"}. Operators should defer to local availability and personal experience in determining which flexible bronchoscope to use (Grade B). There is currently no evidence or consensus to support the safety or efficacy of any individual videolaryngoscope. For ATI:VL practitioners should use videolaryngoscopes with which they are most familiar (Grade B).

Careful selection of tracheal tube is integral to the success of any ATI technique. This should factor in size (internal and external diameter), shape, length, tip design and material. For ATI:FB, reinforced, Parker Flex‐Tip™ (Bridgewater, CN, USA) and intubating laryngeal mask airway tubes (LMA^®^ Fastrach™ ETT, Teleflex, Beaconsfield, UK) have been shown to be superior to standard polyvinylchloride (PVC) tracheal tubes in terms of ease of tracheal intubation, railroading (advancing the tracheal tube over the flexible bronchoscope) and decreasing laryngeal impingement [78](#anae14904-bib-0078){ref-type="ref"}, [79](#anae14904-bib-0079){ref-type="ref"}, [80](#anae14904-bib-0080){ref-type="ref"}, [81](#anae14904-bib-0081){ref-type="ref"}, [82](#anae14904-bib-0082){ref-type="ref"}, [83](#anae14904-bib-0083){ref-type="ref"}, [84](#anae14904-bib-0084){ref-type="ref"}, [85](#anae14904-bib-0085){ref-type="ref"}, [86](#anae14904-bib-0086){ref-type="ref"}. Therefore, the use of a standard PVC tracheal tube is not recommended (Grade A). Using the smallest appropriate external diameter tracheal tube is advisable, as this may reduce the incidence of impingement [87](#anae14904-bib-0087){ref-type="ref"} (Grade B). Positioning the bevel of the tracheal tube posteriorly is recommended [80](#anae14904-bib-0080){ref-type="ref"}, [82](#anae14904-bib-0082){ref-type="ref"}, [86](#anae14904-bib-0086){ref-type="ref"} (Grade A). For ATI:VL, tracheal tube selection is similar to that in an asleep patient and is influenced by the VL selected.

Checklists {#anae14904-sec-0010}
==========

In the peri‐operative setting the use of cognitive aids, such as checklists, improves inter‐professional communication, teamwork and patient outcomes [88](#anae14904-bib-0088){ref-type="ref"}, [89](#anae14904-bib-0089){ref-type="ref"}, [90](#anae14904-bib-0090){ref-type="ref"}, [91](#anae14904-bib-0091){ref-type="ref"}. In anaesthetic practice, cognitive aids enhance performance in simulated emergency scenarios [92](#anae14904-bib-0092){ref-type="ref"}, [93](#anae14904-bib-0093){ref-type="ref"}, and their use been recommended in elective airway management [1](#anae14904-bib-0001){ref-type="ref"}. Given the potential benefits, we recommend a cognitive aid such as a checklist before and during performance of ATI (Grade D; Supporting Information, Appendix [S2](#anae14904-sup-0002){ref-type="supplementary-material"}). The key components of ATI are sedation, topicalisation, oxygenation and performance (sTOP; Fig. [2](#anae14904-fig-0002){ref-type="fig"}). The 's' is in lower case to emphasise the optional nature of sedation.

![The Difficult Airway Society awake tracheal intubation (ATI) technique. This figure forms part of the Difficult Airway Society guidelines for ATI in adults and should be used in conjunction with the text. HFNO, high‐flow nasal oxygen; LA, local anaesthetic; FB, flexible bronchoscopy; MAD, mucosal atomising device; TCI, target‐controlled infusion; Ce, effect‐site concentration; VL, videolaryngoscopy. ©Difficult Airway Society 2019.](ANAE-75-509-g002){#anae14904-fig-0002}

Oxygenation {#anae14904-sec-0011}
===========

The reported incidence of desaturation (S~p~O~2~ ≤ 90%) with low‐flow (\< 30 l.min^−1^) oxygen techniques during ATI ranges between 12% and 16% [58](#anae14904-bib-0058){ref-type="ref"}, [94](#anae14904-bib-0094){ref-type="ref"}, [95](#anae14904-bib-0095){ref-type="ref"}. When warmed and humidified high‐flow nasal oxygen is used, the reported incidence of desaturation is 0--1.5% [33](#anae14904-bib-0033){ref-type="ref"}, [96](#anae14904-bib-0096){ref-type="ref"}; this was the most common oxygenation strategy used by experts responding to our survey. Although there are no randomised controlled trials comparing air vs. oxygen during ATI, data from bronchoscopy studies demonstrate that there is a significant difference in the incidence and severity of desaturation [97](#anae14904-bib-0097){ref-type="ref"}, [98](#anae14904-bib-0098){ref-type="ref"}. In patients receiving sedation in a variety of settings, administration of oxygen has been shown to reduce the incidence of desaturation when compared with air [97](#anae14904-bib-0097){ref-type="ref"}, [99](#anae14904-bib-0099){ref-type="ref"}, [100](#anae14904-bib-0100){ref-type="ref"}, [101](#anae14904-bib-0101){ref-type="ref"}, [102](#anae14904-bib-0102){ref-type="ref"}. United Kingdom, European and North American recommendations for sedation all suggest the use of supplemental oxygen [103](#anae14904-bib-0103){ref-type="ref"}, [104](#anae14904-bib-0104){ref-type="ref"}, [105](#anae14904-bib-0105){ref-type="ref"}. Whilst airway topicalisation alone may rarely be associated with desaturation and airway obstruction [59](#anae14904-bib-0059){ref-type="ref"}, [106](#anae14904-bib-0106){ref-type="ref"}, there is no significant difference in the incidence of desaturation between ATI:FB and ATI:VL techniques, and therefore the recommendations apply to both approaches [31](#anae14904-bib-0031){ref-type="ref"}. The administration of supplemental oxygen during ATI is recommended (Grade B). This should be started on patient arrival for the procedure and continued throughout (Grade D). If available, high‐flow nasal oxygen should be the technique of choice (Grade C).

Airway topicalisation {#anae14904-sec-0012}
=====================

The success of ATI depends on effective topical application of local anaesthetic to the airway. Vasoconstriction of the nasal passage reduces the incidence of epistaxis [107](#anae14904-bib-0107){ref-type="ref"}, [108](#anae14904-bib-0108){ref-type="ref"}. The use of topical nasal vasoconstrictors before nasotracheal intubation is recommended (Grade A).

Lidocaine has theoretical safety benefits over other local anaesthetic agents due to a favourable cardiovascular and systemic toxicity risk profile [109](#anae14904-bib-0109){ref-type="ref"}; this is the most commonly used local anaesthetic agent for ATI. Following airway topicalisation, clinical evidence of toxicity or levels exceeding toxic plasma concentrations have been shown with lidocaine doses of 6.0--9.3 mg.kg^−1^ lean body weight [110](#anae14904-bib-0110){ref-type="ref"}, [111](#anae14904-bib-0111){ref-type="ref"}, [112](#anae14904-bib-0112){ref-type="ref"}, [113](#anae14904-bib-0113){ref-type="ref"}, [114](#anae14904-bib-0114){ref-type="ref"}. The dose of topical lidocaine should not exceed 9 mg.kg^−1^ lean body weight (Grade C) [115](#anae14904-bib-0115){ref-type="ref"}. The recommendation of 9 mg.kg^−1^ rather than 9.3 mg.kg^−1^ is a pragmatic decision to allow ease of calculation. Practitioners should recognise that this is not a target but a maximum dose, and in practice this is rarely required. The total dose of all local anaesthetics administered, regardless of route (e.g. regional anaesthesia or surgical infiltration), must also be considered (Grade D). Some studies have shown that lower concentrations of lidocaine are as effective as higher concentrations [112](#anae14904-bib-0112){ref-type="ref"}, [116](#anae14904-bib-0116){ref-type="ref"}, [117](#anae14904-bib-0117){ref-type="ref"}, [118](#anae14904-bib-0118){ref-type="ref"}, but higher concentrations may be associated with more rapid onset of airway anaesthesia. As with all local techniques, a high index of suspicion of the rare possibility of local anaesthetic toxicity with appropriate training, procedures and emergency drug provision (including lipid emulsion) should be in place [119](#anae14904-bib-0119){ref-type="ref"}, [120](#anae14904-bib-0120){ref-type="ref"}, [121](#anae14904-bib-0121){ref-type="ref"}, [122](#anae14904-bib-0122){ref-type="ref"} (Grade D). The use of cocaine for topicalisation and vasoconstriction can be associated with toxic cardiovascular complications [123](#anae14904-bib-0123){ref-type="ref"}, [124](#anae14904-bib-0124){ref-type="ref"}, [125](#anae14904-bib-0125){ref-type="ref"}, [126](#anae14904-bib-0126){ref-type="ref"}, while its analgesic efficacy during nasotracheal tube insertion is no better than co‐phenylcaine (2.5 ml lidocaine 5%/phenylephrine 0.5%) [127](#anae14904-bib-0127){ref-type="ref"}. Cocaine in this setting is therefore not advised, and phenylephrine in combination with lidocaine is more appropriate (Grade A).

Depending on the delivery device used, there is variable local anaesthetic absorption [128](#anae14904-bib-0128){ref-type="ref"} but this should not affect the maximal dose calculation. There is insufficient evidence to recommend any individual topicalisation technique (e.g. mucosal atomisation, spray‐as‐you‐go, transtracheal injection, nebulisation) [129](#anae14904-bib-0129){ref-type="ref"}. However, blocks of the glossopharyngeal and superior laryngeal nerves have been associated with higher plasma concentrations of local anaesthetic [130](#anae14904-bib-0130){ref-type="ref"}, local anaesthetic systemic toxicity [131](#anae14904-bib-0131){ref-type="ref"} and lower patient comfort [132](#anae14904-bib-0132){ref-type="ref"}. Invasive techniques should therefore be reserved for those with expertise in their performance (Grade B). Nebulised lidocaine can be used but absorption is variable [133](#anae14904-bib-0133){ref-type="ref"}; consequently higher doses have been used to compensate for this [59](#anae14904-bib-0059){ref-type="ref"}. Regardless of technique used, the adequacy of topicalisation should be tested in an atraumatic manner before airway instrumentation [134](#anae14904-bib-0134){ref-type="ref"} (Grade D), for example, with a soft suction catheter or Yankauer sucker.

The use of an antisialogogue is not mandatory in the performance of ATI and may be associated with undesirable clinical consequences (Grade D; Table [3](#anae14904-tbl-0003){ref-type="table"}) [135](#anae14904-bib-0135){ref-type="ref"}. There is limited evidence to support their use in ATI, but in anaesthetised patients the clarity of a visual field through a flexible bronchoscope may be improved [136](#anae14904-bib-0136){ref-type="ref"}. If used, intramuscular antisialogogues should be injected 40--60 min before performing ATI, for peak mucosal drying effect, but there are few data on the intravenous (i.v.) route in this setting.

###### 

Characteristics of drugs used commonly during ATI

+-----------------------+------------------------+---------------+--------------------+-----------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------+
| Class                 | Drug                   | Onset         | Duration of action | Terminal elimination half‐life                                                    | Dosing                                                                                                   | Notes                                                                                                                              |
+=======================+========================+===============+====================+===================================================================================+==========================================================================================================+====================================================================================================================================+
| Antisialogogue        | Glycopyrronium bromide | 20 min (i.m.) | 30--60 min         | 40--80 min                                                                        | 0.2--0.4 mg                                                                                              | Administer 30--60 min pre‐procedure                                                                                                |
+-----------------------+------------------------+---------------+--------------------+-----------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------+
| 3--5 min (i.v.)       | 30--60 min             | 40--80 min    | 0.1--0.2 mg        | May produce significant tachycardia                                               |                                                                                                          |                                                                                                                                    |
+-----------------------+------------------------+---------------+--------------------+-----------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------+
| Atropine              | 20 min (i.m.)          | 30--60 min    | 2 h                | 0.3--0.6 mg                                                                       | Administer 30--60 min pre‐procedure -- less commonly used than glycopyrronium bromide due to tachycardia |                                                                                                                                    |
+-----------------------+------------------------+---------------+--------------------+-----------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------+
| 2--3 min (i.v.)       | 30--60 min             | 2 h           | 0.2--0.3 mg        | May produce significant tachycardia                                               |                                                                                                          |                                                                                                                                    |
+-----------------------+------------------------+---------------+--------------------+-----------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------+
| Hyoscine hydrobromide | 30 min (i.m.)          | 4 h           | 5 h                | 0.2--0.6 mg                                                                       | Administer 30--60 min pre‐procedure                                                                      |                                                                                                                                    |
|                       |                        |               |                    |                                                                                   |                                                                                                          |                                                                                                                                    |
|                       | 5--10 min (i.v.)       |               |                    |                                                                                   | Longer lasting systemic effects than glycopyrronium bromide and atropine                                 |                                                                                                                                    |
|                       |                        |               |                    |                                                                                   |                                                                                                          |                                                                                                                                    |
|                       |                        |               |                    |                                                                                   | May produce tachycardia, dizziness and sedation                                                          |                                                                                                                                    |
+-----------------------+------------------------+---------------+--------------------+-----------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------+
| Topical anaesthesia   | Co‐phenylcaine spray   | 2--5 min      | 30 min             | 1.5--2 h                                                                          | Lidocaine 125 mg                                                                                         | 1 bottle = 2.5 ml of lidocaine 50 mg.ml^−1^ and phenylephrine 5 mg.ml^−1^                                                          |
|                       |                        |               |                    |                                                                                   |                                                                                                          |                                                                                                                                    |
|                       |                        |               |                    |                                                                                   | Phenylephrine 12.5 mg                                                                                    |                                                                                                                                    |
+-----------------------+------------------------+---------------+--------------------+-----------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------+
| Lidocaine 1--10%      | 5 min                  | 30--60 min    | 1.5--2 h           | Total dose not \> 9 mg.kg^−1^ LBW                                                 | 1 ml of 1% = 10 mg                                                                                       |                                                                                                                                    |
|                       |                        |               |                    |                                                                                   |                                                                                                          |                                                                                                                                    |
|                       |                        |               |                    |                                                                                   | 1 spray of 10% = 10 mg                                                                                   |                                                                                                                                    |
+-----------------------+------------------------+---------------+--------------------+-----------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------+
| Cocaine 10%           | 1--3 min               | 30--60 min    | 1 h                | \< 1.5 mg.kg^−1^                                                                  | LD50 1.2 g, but significant toxic effects have been reported at doses as low as 20 mg in adults          |                                                                                                                                    |
|                       |                        |               |                    |                                                                                   |                                                                                                          |                                                                                                                                    |
|                       |                        |               |                    |                                                                                   | Particular care in older patients and/or those with cardiac disease                                      |                                                                                                                                    |
+-----------------------+------------------------+---------------+--------------------+-----------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------+
| Sedatives             | Propofol               | 30 s          | 5--10 min          | 1.5--3 h                                                                          | TCI (effect‐site) 0.5--1 μg.ml^−1^                                                                       | Caution with doses in excess of 1.5 μg.ml^−1^: risk of over‐sedation and hypoventilation, particularly with concomitant opioid use |
|                       |                        |               |                    |                                                                                   |                                                                                                          |                                                                                                                                    |
|                       |                        |               |                    |                                                                                   |                                                                                                          | Avoid bolus dosing                                                                                                                 |
+-----------------------+------------------------+---------------+--------------------+-----------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------+
| Midazolam             | 3--5 min               | 1--2 h        | 1.5--3 h           | Bolus 0.5--1 mg                                                                   | Titrate to effect                                                                                        |                                                                                                                                    |
|                       |                        |               |                    |                                                                                   |                                                                                                          |                                                                                                                                    |
|                       |                        |               |                    |                                                                                   | Peak effect at 5--10 min so care with multiple doses                                                     |                                                                                                                                    |
+-----------------------+------------------------+---------------+--------------------+-----------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------+
| Dexmedetomidine       | 1--2 min               | 5--10 min     | 2 h                | Bolus 0.5--1 μg.kg^−1^ over 5 min followed by infusion (0.3--0.6 μg.kg^−1^.h^−1^) | Caution with bolus dosing as associated with hypertension and bradycardia                                |                                                                                                                                    |
+-----------------------+------------------------+---------------+--------------------+-----------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------+
| Analgesia             | Remifentanil           | 1 min         | 3--5 min           | 1--20 min                                                                         | TCI (effect‐site) 1--3 ng.ml^−1^                                                                         | Caution with respiratory depression.                                                                                               |
|                       |                        |               |                    |                                                                                   |                                                                                                          |                                                                                                                                    |
|                       |                        |               |                    |                                                                                   |                                                                                                          | Avoid bolus dosing.                                                                                                                |
+-----------------------+------------------------+---------------+--------------------+-----------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------+
| Fentanyl              | 2--5 min               | 30--60 min    | 6--10 min          | Bolus 0.5--1 μg.kg^−1^, subsequent doses of 0.5 μg.kg^−1^ as required             |                                                                                                          |                                                                                                                                    |
+-----------------------+------------------------+---------------+--------------------+-----------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------+
| Alfentanil            | 2--3 min               | 15 min        | 90--120 min        | Bolus 5 μg.kg^−1^, subsequent doses of 1--3 μg.kg^−1^ as required                 |                                                                                                          |                                                                                                                                    |
+-----------------------+------------------------+---------------+--------------------+-----------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------+

ATI, awake tracheal intubation; i.m., intramuscular; i.v., intravenous; TCI, target‐controlled infusion; LD50, median lethal dose; LBW, lean body weight.
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Sedation {#anae14904-sec-0013}
========

Awake tracheal intubation may be safely and effectively performed without sedation [33](#anae14904-bib-0033){ref-type="ref"}, [59](#anae14904-bib-0059){ref-type="ref"}, [60](#anae14904-bib-0060){ref-type="ref"}. However, its use during ATI can reduce patient anxiety and discomfort and increase procedural tolerance [137](#anae14904-bib-0137){ref-type="ref"}. Minimal sedation is defined as "*a drug‐induced state during which the patient responds normally to verbal commands, whilst the airway, spontaneous ventilation and cardiovascular function are unaffected*" [138](#anae14904-bib-0138){ref-type="ref"}. Sedative drugs can produce a number of effects which may be considered desirable (e.g. amnesia) or detrimental (e.g. over‐sedation). The risk of over‐sedation and its sequelae, including respiratory depression, airway loss, hypoxia, aspiration and cardiovascular instability, make the presence of an independent anaesthetist delivering, monitoring and titrating sedation desirable [1](#anae14904-bib-0001){ref-type="ref"} (Grade D). In certain patient populations, the risk of over‐sedation is particularly hazardous, thus an independent practitioner delivering sedation is strongly recommended (Grade D; Table [4](#anae14904-tbl-0004){ref-type="table"}). If required, we recommend the cautious use of minimal sedation (Grade D).

###### 

Special circumstances that may affect standard performance of ATI with suggested management options

+------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+-----------------------------------------------+
| Special circumstance                                                                                             | Considerations                                                                          | Modification                                                                              | Potential management options                  |
+==================================================================================================================+=========================================================================================+===========================================================================================+===============================================+
| Critically ill                                                                                                   | Limited physiological reserve and greater adverse consequences associated with sedation | Sedation                                                                                  | Avoid or minimise sedation                    |
+------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+-----------------------------------------------+
| Higher risk of local anaesthetic systemic toxicity                                                               | Topicalisation                                                                          | Cautious use of local anaesthetic                                                         |                                               |
|                                                                                                                  |                                                                                         |                                                                                           |                                               |
| Increased secretions                                                                                             |                                                                                         | Suction airway before instrumentation                                                     |                                               |
+------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+-----------------------------------------------+
| Increased oxygen demand and reduced oxygen reserves                                                              | Oxygenation                                                                             | Supplemental oxygen essential                                                             |                                               |
+------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+-----------------------------------------------+
| Unstable for transfer to operating theatre                                                                       | Performance                                                                             | Do not transfer patient out of critical care settings                                     |                                               |
|                                                                                                                  |                                                                                         |                                                                                           |                                               |
|                                                                                                                  |                                                                                         | Maintain same standards of equipment and monitoring                                       |                                               |
|                                                                                                                  |                                                                                         |                                                                                           |                                               |
|                                                                                                                  |                                                                                         | Time‐critical performance of ATI                                                          |                                               |
|                                                                                                                  |                                                                                         |                                                                                           |                                               |
|                                                                                                                  |                                                                                         | Early consideration for high‐risk general anaesthesia                                     |                                               |
+------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+-----------------------------------------------+
| Obstetrics                                                                                                       | Fetal sedation with benzodiazepines, long‐acting opioids or propofol                    | Sedation                                                                                  | Sedation with dexmedetomidine or remifentanil |
|                                                                                                                  |                                                                                         |                                                                                           |                                               |
|                                                                                                                  |                                                                                         |                                                                                           | Warn neonatologists                           |
+------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+-----------------------------------------------+
| Higher risk of local anaesthetic systemic toxicity; concomitant use of local anaesthetics via epidural analgesia | Topicalisation                                                                          | Cautious dosing of local anaesthetic; consider using pre‐pregnancy body weight for dosing |                                               |
+------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+-----------------------------------------------+
| Increased oxygen demand and reduced oxygen reserves                                                              | Oxygenation                                                                             | Supplemental oxygen essential                                                             |                                               |
+------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+-----------------------------------------------+
| Increased upper airway oedema and perfusion thus increasing risk of nasal haemorrhage                            | Performance                                                                             | Oral approach to ATI                                                                      |                                               |
|                                                                                                                  |                                                                                         |                                                                                           |                                               |
| FONA more difficult                                                                                              |                                                                                         | Identify and mark cricothyroid membrane early                                             |                                               |
|                                                                                                                  |                                                                                         |                                                                                           |                                               |
|                                                                                                                  |                                                                                         | Airway ultrasound to identify cricothyroid membrane                                       |                                               |
+------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+-----------------------------------------------+
| Obesity                                                                                                          | Critical adverse consequences of over‐sedation                                          | Sedation                                                                                  | Avoid or minimise sedation                    |
+------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+-----------------------------------------------+
| Risk of local anaesthetic overdose                                                                               | Topicalisation                                                                          | Local anaesthetic dosing on lean body weight                                              |                                               |
+------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+-----------------------------------------------+
| Increased oxygen demand and reduced oxygen reserves                                                              | Oxygenation                                                                             | Supplemental oxygen essential                                                             |                                               |
+------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+-----------------------------------------------+
| Diaphragmatic splinting and reduced functional residual capacity                                                 | Performance                                                                             | Sitting position or reverse Trendelenburg                                                 |                                               |
|                                                                                                                  |                                                                                         |                                                                                           |                                               |
|                                                                                                                  |                                                                                         | Operator facing patient                                                                   |                                               |
+------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+-----------------------------------------------+
| FONA more difficult                                                                                              | Identify and mark cricothyroid membrane early                                           |                                                                                           |                                               |
|                                                                                                                  |                                                                                         |                                                                                           |                                               |
|                                                                                                                  | Airway ultrasound to identify cricothyroid membrane                                     |                                                                                           |                                               |
+------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+-----------------------------------------------+
| Trauma                                                                                                           | Critical adverse consequences of over‐sedation                                          | Sedation                                                                                  | Avoid or minimise sedation                    |
+------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+-----------------------------------------------+
| Difficult administration due to airway soiling                                                                   | Topicalisation                                                                          | Clear soiled airway before topicalisation                                                 |                                               |
+------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+-----------------------------------------------+
| Increased oxygen demand and reduced oxygen reserves                                                              | Oxygenation                                                                             | Supplemental oxygen essential                                                             |                                               |
+------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+-----------------------------------------------+
| Unstable for transfer to operating theatre                                                                       | Performance                                                                             | Do not transfer patient out of critical care settings                                     |                                               |
|                                                                                                                  |                                                                                         |                                                                                           |                                               |
|                                                                                                                  |                                                                                         | Maintain same standards of equipment and monitoring                                       |                                               |
+------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+-----------------------------------------------+
| Airway soiling from haemorrhage, secretions, vomitus and tissue oedema                                           | ATI: VL                                                                                 |                                                                                           |                                               |
|                                                                                                                  |                                                                                         |                                                                                           |                                               |
|                                                                                                                  | Tracheal intubation via SAD                                                             |                                                                                           |                                               |
+------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+-----------------------------------------------+
| Suspected base of skull or facial fracture                                                                       |                                                                                         | Avoid HFNO                                                                                |                                               |
|                                                                                                                  |                                                                                         |                                                                                           |                                               |
|                                                                                                                  |                                                                                         | Oral approach to ATI                                                                      |                                               |
+------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+-----------------------------------------------+
| Trismus                                                                                                          | Critical adverse consequences of over‐sedation                                          | Sedation                                                                                  | Avoid or minimise sedation                    |
+------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+-----------------------------------------------+
| Limited pharyngeal access                                                                                        | Topicalisation                                                                          | Nebulised lidocaine                                                                       |                                               |
|                                                                                                                  |                                                                                         |                                                                                           |                                               |
|                                                                                                                  |                                                                                         | Spray‐as‐you‐go                                                                           |                                               |
|                                                                                                                  |                                                                                         |                                                                                           |                                               |
|                                                                                                                  |                                                                                         | Transtracheal lidocaine injection                                                         |                                               |
|                                                                                                                  |                                                                                         |                                                                                           |                                               |
|                                                                                                                  |                                                                                         | Insertion of mucosal atomiser and patient gargling                                        |                                               |
+------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+-----------------------------------------------+
| Potentially increased oxygen demand                                                                              | Oxygenation                                                                             | Supplemental oxygen essential                                                             |                                               |
+------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+-----------------------------------------------+
| Limited mouth opening                                                                                            | Performance                                                                             | Nasal approach to ATI: FB                                                                 |                                               |
+------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+-----------------------------------------------+
| Stridor                                                                                                          | Critical adverse consequences of over‐sedation                                          | Sedation                                                                                  | Avoid or minimise sedation                    |
+------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+-----------------------------------------------+
| Risk of laryngospasm                                                                                             | Topicalisation                                                                          | Consider nebulised and/or lower concentrations of lidocaine                               |                                               |
+------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+-----------------------------------------------+
| Airway obstruction                                                                                               | Oxygenation                                                                             | HFNO highly recommended                                                                   |                                               |
+------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+-----------------------------------------------+
| Narrowed airway                                                                                                  | Performance                                                                             | Recognise that airway narrowing may preclude oral or nasal tracheal intubation            |                                               |
|                                                                                                                  |                                                                                         |                                                                                           |                                               |
|                                                                                                                  |                                                                                         | Prime for emergency FONA                                                                  |                                               |
|                                                                                                                  |                                                                                         |                                                                                           |                                               |
|                                                                                                                  |                                                                                         | Use smaller tracheal tube                                                                 |                                               |
|                                                                                                                  |                                                                                         |                                                                                           |                                               |
|                                                                                                                  |                                                                                         | Most experienced practitioner to perform                                                  |                                               |
|                                                                                                                  |                                                                                         |                                                                                           |                                               |
|                                                                                                                  |                                                                                         | May require combined technique                                                            |                                               |
+------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------+-----------------------------------------------+

ATI, awake tracheal intubation; VL, videolaryngoscopy; SAD, supraglottic airway device; HFNO, high‐flow nasal oxygen; FB, flexible bronchoscopy; FONA, front‐of‐neck airway.
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Remifentanil and dexmedetomidine are associated with high levels of patient satisfaction and low risk of over‐sedation and airway obstruction when used for ATI [137](#anae14904-bib-0137){ref-type="ref"}. A single‐agent strategy is safest for the non‐expert, and if used, remifentanil or dexmedetomidine are appropriate (Grade A). As a sole sedative agent, propofol is associated with a greater risk of over‐sedation, coughing and airway obstruction than remifentanil [139](#anae14904-bib-0139){ref-type="ref"}, [140](#anae14904-bib-0140){ref-type="ref"}, [141](#anae14904-bib-0141){ref-type="ref"} and is therefore not advisable in this setting (Grade A) [137](#anae14904-bib-0137){ref-type="ref"}. If co‐administration of sedative agents is to be performed, remifentanil and midazolam are both reversible and therefore appropriate, recognising the increased risk of over‐sedation (Grade D). Sedation should not be used as a substitute for inadequate airway topicalisation (Grade D) [129](#anae14904-bib-0129){ref-type="ref"}. A suggested sedation regimen is presented in Fig. [2](#anae14904-fig-0002){ref-type="fig"}.

Two‐point check of tracheal tube placement {#anae14904-sec-0014}
==========================================

Awake tracheal intubation can result in incorrect tracheal tube placement, including pharyngeal, oesophageal or bronchial intubation. Oesophageal intubation occurs in 2.3% of procedures with ATI:FB and 4.9% with ATI:VL [58](#anae14904-bib-0058){ref-type="ref"}. Capnography has 100% sensitivity and specificity in identifying correct tracheal tube positioning in patients who lungs are ventilated [142](#anae14904-bib-0142){ref-type="ref"}, [143](#anae14904-bib-0143){ref-type="ref"}. However, in a patient who is spontaneously breathing, a capnographic trace may also be seen with supraglottic or bronchial placement of the tracheal tube. A two‐point check is therefore required to confirm the position of the tracheal tube: visualisation of the tracheal lumen with ATI:FB or the tracheal tube through the vocal cords with ATI:VL to confirm tracheal placement; andcapnography to exclude oesophageal intubation (Grade C)

Anaesthesia should be induced only when the two‐point check has confirmed correct tracheal tube placement (Grade D). Once the flexible bronchoscope is in the trachea, the carina should be identified before advancing the tracheal tube to minimise the risk of misplacement (Grade D). The distance from the tracheal tube tip to the carina should be confirmed as appropriate before removing the bronchoscope (Grade D). On removal of the flexible bronchoscope or videolaryngoscope, care must be taken to maintain the correct position of the tracheal tube. The tip of the bronchoscope should be in the neutral position and the tracheal tube held firmly in position (Grade D). The tracheal tube cuff can be gently inflated before, during or after induction of anaesthesia. The decision around timing of cuff inflation should be guided by the relative risks of aspiration, patient movement, coughing and tracheal tube displacement (Grade D). If there is suspicion of a cuff tear, gentle inflation of the cuff to check integrity before induction of anaesthesia is recommended (Grade D).

Difficult Airway Society ATI technique {#anae14904-sec-0015}
======================================

An example of a practical approach to the sTOP ATI technique is shown in Fig. [2](#anae14904-fig-0002){ref-type="fig"}. This technique has been specifically considered for simplicity and generalisability. We recognise that there are a range of different techniques and regimens which also address the key sTOP components that will be equally effective.

Special circumstances {#anae14904-sec-0016}
=====================

Specific patient pathophysiology may dictate modifications to the performance of ATI that must be considered and planned for. As with all other aspects of ATI, these modifications can be categorised based on sTOP. Examples of suggested changes to technique are presented in Table [4](#anae14904-tbl-0004){ref-type="table"}.

Managing complications {#anae14904-sec-0017}
======================

The reported overall complication rate in patients undergoing ATI either flexible bronchoscopic or videolaryngoscopic, is up to 18% [33](#anae14904-bib-0033){ref-type="ref"}, [34](#anae14904-bib-0034){ref-type="ref"}, [35](#anae14904-bib-0035){ref-type="ref"}, [58](#anae14904-bib-0058){ref-type="ref"}, [144](#anae14904-bib-0144){ref-type="ref"}, [145](#anae14904-bib-0145){ref-type="ref"}, [146](#anae14904-bib-0146){ref-type="ref"}. Complications during ATI occur due to inadequate sTOP. In the event of a complication, its aetiology should be determined and appropriately managed (Grade D; Fig. [3](#anae14904-fig-0003){ref-type="fig"}).

![Managing procedural complications during awake tracheal intubation (ATI). This provides a framework for managing complications, but is not meant to be a comprehensive guide. This figure forms part of the Difficult Airway Society guidelines for ATI in adults and should be used in conjunction with the text. F~I~O~2~, fractional inspired concentration of oxygen; O~2~, oxygen ©Difficult Airway Society 2019.](ANAE-75-509-g003){#anae14904-fig-0003}

We define an unsuccessful attempt at ATI as the unplanned removal of flexible bronchoscope, videolaryngoscope or tracheal tube from the airway. Patients in whom ATI is indicated are at greater risk of the adverse consequences of multiple attempts, such as airway trauma, airway obstruction, bleeding and unsuccessful ATI [1](#anae14904-bib-0001){ref-type="ref"}. It is therefore advisable to minimise the number of attempts at ATI (Grade D). Operators should consider if they require more experienced support before commencing ATI (Grade D). Operators should ensure sTOP is optimised before the first attempt (Grade D). If unsuccessful with the first attempt, operators should re‐assess, correct any inadequate sTOP components, and call for help before proceeding with a second attempt (Grade D). If unsuccessful with the second attempt, a third may be considered only if conditions can be further optimised (Grade D). A fourth and final attempt (3 + 1) should only be undertaken by a more experienced operator, which may include a surgeon (Grade D). Each attempt subsequent to the first should involve a change in the elements of performance to improve the likelihood of success (Grade D). The use of an alternative device (e.g. FB to VL or vice versa) should be counted in the total number of attempts. Each failed attempt may adversely affect patient and operator confidence. Seeking expert help at the earliest opportunity is recommended (Grade D). If unsuccessful after 3 + 1 attempts, the unsuccessful ATI algorithm should be followed (Grade D; Fig. [4](#anae14904-fig-0004){ref-type="fig"}).

![The Difficult Airway Society management of unsuccessful awake tracheal intubation (ATI) in adults. This algorithm forms part of the Difficult Airway Society guidelines for ATI in adults and should be used in conjunction with the text. HFNO, high‐flow nasal oxygen; SAD, supraglottic airway device; FONA, front‐of‐neck airway; GA, general anaesthesia. ©Difficult Airway Society 2019.](ANAE-75-509-g004){#anae14904-fig-0004}

Management of unsuccessful ATI {#anae14904-sec-0018}
==============================

The unsuccessful ATI algorithm is a guide for the rare occasions where successful tracheal intubation has not been achieved in 3 + 1 attempts. Immediate actions should include a call for help, ensuring 100% oxygen is applied and stopping (if necessary, reversing) any sedative drugs (Grade D). Operators should 'stop and think' to determine subsequent airway management, while also 'priming' for emergency FONA [2](#anae14904-bib-0002){ref-type="ref"}, [52](#anae14904-bib-0052){ref-type="ref"} (Grade D). The default action in the event of unsuccessful ATI should be to postpone the procedure (Grade D). Operators should only proceed with immediate airway management if essential (e.g. if airway patency, ventilation or neurology is compromised; urgent or immediate surgery is required; or clinical deterioration is expected) (Grade D).

If airway management is deemed essential, the preferred option for securing the airway after unsuccessful ATI:VL or ATI:FB should be ATI using FONA (ATI:FONA), which includes cricothyroidotomy or tracheostomy (Grade D). The most appropriately skilled clinician available should perform this (Grade C). The considerations for the appropriateness of ATI:FONA include: patient factors; skill; and equipment availability. If inappropriate or unsuccessful, a high‐risk general anaesthetic is the only remaining option. In this scenario, the operator should formulate an achievable A to D airway management strategy informed by the unsuccessful attempts at ATI and based on the 2015 DAS guidelines [2](#anae14904-bib-0002){ref-type="ref"}, recognising that they are primarily for the unanticipated difficult tracheal intubation (Grade D). This strategy should include an i.v. induction of anaesthesia with full neuromuscular blockade [2](#anae14904-bib-0002){ref-type="ref"}, [52](#anae14904-bib-0052){ref-type="ref"} (Grade D). Videolaryngoscopes may improve tracheal intubation success rates in cases of difficult tracheal intubation [147](#anae14904-bib-0147){ref-type="ref"}; therefore, the first attempt at tracheal intubation in this scenario should be with a videolaryngoscope (Grade A). All attempts with any device should be performed by the most appropriately skilled clinician present (Grade C).

Post‐tracheal intubation management {#anae14904-sec-0019}
===================================

Patients who have had ATI due to predicted difficult airway management are at high risk of complications at tracheal extubation [1](#anae14904-bib-0001){ref-type="ref"}, [148](#anae14904-bib-0148){ref-type="ref"}, and require an appropriate tracheal extubation strategy. Planning, preparation, performing and post‐tracheal extubation care should follow DAS guidelines [148](#anae14904-bib-0148){ref-type="ref"} (Grade D).

Before tracheal extubation, laryngoscopy, either with a direct laryngoscope or videolaryngoscope, may provide useful information for risk stratification of tracheal extubation and any subsequent airway management. The view at laryngoscopy may be altered by the presence of a tracheal tube [148](#anae14904-bib-0148){ref-type="ref"}. Therefore, verification of laryngoscopy grade may rule out, but not rule in, easy subsequent asleep tracheal intubation.

Topical lidocaine has a dose‐dependent duration of analgesic action of up to 40 min although this may vary with concentration and method of administration [149](#anae14904-bib-0149){ref-type="ref"}, [150](#anae14904-bib-0150){ref-type="ref"}. However, the time to return of laryngeal reflexes can be longer [151](#anae14904-bib-0151){ref-type="ref"}. Given that the terminal elimination half‐life of lidocaine is up to 2 h, patients should remain nil by mouth for at least 2 h following airway topicalisation for ATI (Grade D).

Documentation of ATI in clinical records is necessary to inform and guide future patient management [1](#anae14904-bib-0001){ref-type="ref"}, [152](#anae14904-bib-0152){ref-type="ref"}. This should include: documentation of oxygenation; topicalisation; sedation strategy; device and tracheal tube used; approach (e.g. right nasal, left nasal, oral); number of attempts; and any complications or notes (Grade D; Supporting Information, Appendix [S3](#anae14904-sup-0003){ref-type="supplementary-material"}).

Consent {#anae14904-sec-0020}
=======

Clinicians should adhere to the Association of Anaesthetists' guidelines on consent for anaesthesia [153](#anae14904-bib-0153){ref-type="ref"} (Grade D). Informed consent must be taken, with patients being given information (ideally including a patient information leaflet [154](#anae14904-bib-0154){ref-type="ref"}) in a timely manner (Grade D). The risks of ATI and its alternative (induction of general anaesthesia before securing the airway) should be discussed (Table [5](#anae14904-tbl-0005){ref-type="table"}) (Grade D). Appropriate explanation is vital and a good rapport can increase the confidence and co‐operation of the patient in the procedure and is strongly encouraged (Grade D). The consent process should be documented (Grade D).

###### 

Incidence of complications when asleep or awake tracheal intubation is performed. The rates reported for asleep tracheal intubation include data for all patients, and patients who are predicted to have difficult airway management. The rates reported for awake tracheal intubation are only for patients who are predicted to be at risk of difficult airway management

                                    Asleep tracheal intubation   Awake tracheal intubation                       
  --------------------------------- ---------------------------- ----------------------------------------------- -------------------------
  Difficult facemask ventilation    2.2--2.5%                    18.6--22%                                       Not applicable
  Impossible facemask ventilation   0.15%                        Not currently available                         Not applicable
  Difficult tracheal intubation     1.9--10%                     25%                                             Not applicable
  Failed tracheal intubation        0.15%                        0.36%[a](#anae14904-note-0006){ref-type="fn"}   1--2%
  CICO                              0.04%                        0.75%[a](#anae14904-note-0006){ref-type="fn"}   0--0.06%
  Front‐of‐neck airway              0.002--0.07%                 0.12%[a](#anae14904-note-0006){ref-type="fn"}   0--0.38%
  Death                             0.0006--0.04%                Not currently available                         Not currently available

CICO, cannot intubate, cannot oxygenate.

Unpublished data from the Danish Anaesthesia Database.

John Wiley & Sons, Ltd

Training {#anae14904-sec-0021}
========

Successful performance of ATI has been shown to be independent of seniority, but related to experience [33](#anae14904-bib-0033){ref-type="ref"}. There are many strategies used for training in the technical aspects of ATI, including the use of manikins, simulators, cadavers and patients [59](#anae14904-bib-0059){ref-type="ref"}, [155](#anae14904-bib-0155){ref-type="ref"}, [156](#anae14904-bib-0156){ref-type="ref"}, [157](#anae14904-bib-0157){ref-type="ref"}, [158](#anae14904-bib-0158){ref-type="ref"}, [159](#anae14904-bib-0159){ref-type="ref"}, [160](#anae14904-bib-0160){ref-type="ref"}, [161](#anae14904-bib-0161){ref-type="ref"}. All anaesthetists should seek every opportunity to attain and maintain skills in ATI and all departments should support this [1](#anae14904-bib-0001){ref-type="ref"} (Grade C). Awake tracheal intubation is a skill in the compulsory higher training curriculum of the Royal College of Anaesthetists [162](#anae14904-bib-0162){ref-type="ref"}, but opportunities for training are known to be limited [163](#anae14904-bib-0163){ref-type="ref"}, [164](#anae14904-bib-0164){ref-type="ref"}, [165](#anae14904-bib-0165){ref-type="ref"}, [166](#anae14904-bib-0166){ref-type="ref"}, [167](#anae14904-bib-0167){ref-type="ref"}. These guidelines provide a common stem for sedation, topicalisation, oxygenation and performance to encourage training in ATI. Experience using a range of tools should be sought, complementing active clinical practice to develop non‐technical aspects of ATI (Grade B). We recognise this may be difficult to achieve [163](#anae14904-bib-0163){ref-type="ref"}, [164](#anae14904-bib-0164){ref-type="ref"}, [165](#anae14904-bib-0165){ref-type="ref"}, [166](#anae14904-bib-0166){ref-type="ref"}, [167](#anae14904-bib-0167){ref-type="ref"}, but local hospital airway leads are ideally placed to facilitate training and provision of ATI skills and equipment. Team training in ATI should include anaesthetic assistants, operating department practitioners and theatre staff. Awake tracheal intubation may be performed solely for the purposes of training provided appropriate consent is taken (Grade D).

Future directions {#anae14904-sec-0022}
=================

These guidelines highlight the paucity of high‐quality evidence in ATI, as demonstrated by the need for expert opinion for the majority of recommendations. This presents an opportunity for further research to be undertaken to improve both clinical and patient‐centred outcomes [168](#anae14904-bib-0168){ref-type="ref"}. In particular, the ideal topicalisation and sedation strategies are yet to be elucidated, with a limited evidence base for individual drugs, administration methods (e.g. infusion vs. bolus, combinations of sedatives, mucosal atomiser vs. nebulisation) and their related outcomes [129](#anae14904-bib-0129){ref-type="ref"}. There remains uncertainty regarding many aspects of procedural performance such as ideal patient and operator positioning, the role of checklists and cognitive aids and immediate management of complications. Moreover, training in ATI has thus far focussed on technical aspects, primarily with FB, but training with alternative devices and non‐technical skills have had little attention in the published literature and warrant further investigation. Novel technology for ATI must also be developed, such as improved capnography and monitoring, safer sedation delivery devices and better image visualisation and guidance technology. Finally, the impact these guidelines have on clinical practice should be examined to allow further iterations to be improved upon. This will require updates of these guidelines using similar methodology when a more robust evidence base becomes available.

Discussion {#anae14904-sec-0023}
==========

The primary aims of these guidelines are to provide practitioners with a comprehensive document on ATI. These guidelines should support clinical practice and lower the performance threshold thereby increasing the use of ATI when indicated. The quality of evidence supporting many recommendations is limited, with interventions and outcomes being highly heterogeneous. This is likely influenced by the fact that ATI can be successfully performed in a wide range of settings and patients with varying techniques [129](#anae14904-bib-0129){ref-type="ref"}. For example, the use of SADs as a conduit to ATI or optical stylets in awake patients have not been well‐described but warrant future investigation as their role becomes more defined. Similarly, the lack of previously published specific guidelines means that research in ATI is disparate and inconsistent [169](#anae14904-bib-0169){ref-type="ref"}. However, we have sought and appraised the available evidence in ATI, and in its absence we have incorporated the practical and theoretical experience of international experts. We have involved patients, DAS members and international experts in order to further understand current practice and the need for these guidelines. Formal resource implication analysis has not been conducted; however, the tools to practically perform ATI are available widely, and thus we expect the resource impact to be modest.

These guidelines prioritise patient safety and provide recommendations for best clinical practice. It is hoped that they will lead to a paradigm shift in clinical practice and improve the care of patients with predicted difficult airway management in the UK and beyond.
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======================
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**Appendix S1.** Summary of the systematic review methodology.
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Click here for additional data file.
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**Appendix S2.** The Difficult Airway Society checklist for awake tracheal intubation (ATI) in adults. SAD, supraglottic airway device.
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Click here for additional data file.
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**Appendix S3.** The Difficult Airway Society documentation sticker for awake tracheal intubation (ATI) in adults. FB, flexible bronchoscopy; VL, videolaryngoscopy; L, left; R, right.
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Click here for additional data file.
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